- Home
- MIRM vs LEA Comparison
MIRM vs LEA Comparison
Compare MIRM & LEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | LEA |
|---|---|---|
| Founded | 2018 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.3B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | LEA |
|---|---|---|
| Price | $93.42 | $120.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $119.85 | ★ $132.21 |
| AVG Volume (30 Days) | 456.7K | ★ 536.1K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 7.13 |
| Revenue | $19,138,000.00 | ★ $23,259,100,000.00 |
| Revenue This Year | $26.22 | $2.50 |
| Revenue Next Year | $22.04 | $3.12 |
| P/E Ratio | ★ N/A | $17.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.23 | $96.04 |
| 52 Week High | $130.00 | $150.33 |
Technical Indicators
Market Signals| Indicator | MIRM | LEA |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 38.19 |
| Support Level | $88.08 | $116.08 |
| Resistance Level | $98.03 | $123.21 |
| Average True Range (ATR) | 3.82 | 3.48 |
| MACD | -0.03 | -0.51 |
| Stochastic Oscillator | 1.32 | 5.14 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.